Theranostics News and Research

RSS

New procedure standard/practice guideline released for fibroblast activation protein PET

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET.

25 Jan 2025

Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

3 Jan 2025

New molecular imaging agent can accurately identify crucial cancer biomarker

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer.

18 Dec 2024

AI and imaging tools to drive personalized cancer treatments in Europe

Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies ("Theranostics") to target cancer first at the "diagnosis" phase and then at the "therapy" phase, using the same biological targets ("see to treat").

8 Oct 2024

Extending survival in meningioma patients with innovative radiopharmaceutical therapy

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor.

29 Sep 2024

New fluorescent probe offers non-invasive detection of smell loss

A new fluorescent imaging probe can for the first time objectively and non-invasively measure loss of smell, clinically known as anosmia.

20 Aug 2024

MGI Tech shares new data on core DNEBSEQ technology and showcases latest sequencing innovations at ESHG 2024

MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today showcased its cutting-edge technologies via a Corporate Satellite Meeting at this year’s European Society of Human Genetics (ESHG) conference in Berlin, Germany.

From MGI 7 Jun 2024

Novel PET radiotracer enables same-day imaging of gastrointestinal cancer biomarker

A new PET radiotracer enables same-day imaging of the important gastrointestinal cancer biomarker known as Claudin18.2 (CLDN18.2).

6 Jun 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

New PET imaging biomarker Gal-1 predicts tumor responses to immunotherapy

The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning treatment.

15 May 2024

New PET imaging agent shows promise in visualizing lesions in clear cell renal cell cancer patients

A novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of The Journal of Nuclear Medicine.

7 May 2024

Breakthrough imaging method enhances precision in prostate cancer treatment

A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

17 Apr 2024

PET/MRI combination reduces unnecessary prostate biopsies, study shows

PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in the April issue of The Journal of Nuclear Medicine.

13 Apr 2024

Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine.

4 Apr 2024

Lancet Commission predicts sharp increase in global prostate cancer cases

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs) predicted to see the highest increases in cases, according to The Lancet Commission on prostate cancer which will be launched by a presentation at the European Association of Urology Congress.

4 Apr 2024

New method for detecting and treating breast cancer subtypes

The most prevalent disease in women, breast cancer, poses a major risk to the health of women.

2 Apr 2024

New DNA nanomachine targets breast cancer with precision

Breast cancer is the most common malignancy in women, posing a serious threat to the female health. Due to the high inter- and intra-tumoral heterogeneity of breast cancer, clinical treatment and prognosis can vary greatly in patients.

28 Mar 2024

New method developed for triggering and imaging seizures in epilepsy patients

Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery.

11 Mar 2024

New PET radiotracer distinguishes diseased tissues based on fructose metabolism

A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in the March issue of The Journal of Nuclear Medicine.

8 Mar 2024

Collaborative project gets $20 million to develop new radiopharmaceutical cancer therapies

UT Health Science Center researchers Gabor Tigyi, MD, PhD, Harriet Van Vleet Endowment Professor in Basic Oncology Research, Junming Yue, PhD, associate professor in the Department of Pathology, Sue Chin Lee, PhD, in the Department of Physiology, and David Schwartz, MD, chair of the Department of Radiation Oncology, are part of a scientific leadership group awarded $20 million from the University of Tennessee-Oak Ridge Innovation Institute in partnership with Oak Ridge National Laboratory and the University of Tennessee, Knoxville, to develop new radiopharmaceutical therapies to treat cancer.

21 Feb 2024